Drugs / HM10660A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01504581 | Mar → Sep 2011 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02057887 | Jul 2013 → Aug 2014 | chronic hepatitis C virus infection | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM10660A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057887 ↗ |
| Known as | LAPS-INTERFERON ALPHA-2B | “A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of The Pharmacokinetics, Pharmacodynamics And Safety Of Single Ascending Doses Of HM10660A (LAPS-INTERFERON...” NCT01504581 ↗ |
| Modality | Protein / enzyme biologic | “Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)” NCT02057887 ↗ |